痛风患者脂代谢、甲状腺激素及炎症因子水平的变化研究

Changes of lipid metabolism,thyroid hormones and inflammatory factors in patients with gout

目的:研究痛风患者脂代谢、甲状腺激素及炎症因子水平的变化。方法:选取我院2014年12月至2016年12月95例痛风患者为研究对象,根据痛风自然病程将纳入患者分为急性期组(n=58)与间歇期组(n=37)。选取同期在我院进行体检的50例健康志愿者为健康组。比较不同组患者与健康志愿者的血脂水平、甲状腺功能减退症(甲减)与亚临床型甲状腺功能减退症(亚临床甲减)检出率、炎症因子指标。结果:急性期组总胆固醇(TC)、三酰甘油(TG)、超敏C反应蛋白(hs-CRP)分别为(5.65±1.22)mmol/L、(2.03±0.74)mmol/L、(31.77±12.24)mg/L显著高于间歇期组与健康组(P<0.05)。急性期组亚临床甲减检出率12.1%显著高于健康组0%(P<0.05)。间歇期组TC、TG、亚临床甲减检出率、hs-CRP分别为(5.08±1.24)mmol/L、(1.61±0.79)mmol/L、8.1%、(9.38±3.45)mg/L显著高于健康组的(3.86±0.77)mmol/L、(0.92±0.35)mmol/L、0.0%、(6.26±1.28)mg/L(P<0.05)。急性期组和间歇期组亚临床甲减检出率比较差异无统计学意义(P>0.05)。结论:随着痛风病情发展患者血脂、炎症因子水平上升,部分患者出现亚临床甲减。对痛风患者应关注甲状腺功能,需采用积极综合干预手段调脂抗炎,保护甲状腺功能,防止病情进一步发展。

Objective：To study the changes of lipid metabolism,thyroid hormones and inflammatory factors in patients with gout.Methods：A total of 95 patients with gout treated in our hospital from December 2014 to December 2016 were selected as the study subjects.According to the natural course of gout,the patients were divided into acute group（n = 58） and intermittent group（n = 37）.Another 50 healthy volunteers were selected as healthy group in the same period.The levels of blood lipids,detection rates of hypothyroidism and subclinical hypothyroidism and inflammatory factors were compared between groups.Results：Levels of total cholesterol（TC）,triglyceride（TG） and high sensitivity C reactive protein（hs-CRP） [（5.65±1.22） mmol/L,（2.03±0.74） mmol/L,（31.77±12.24） mg/L] were significantly higher in acute group than intermittent group and healthy group（P〈0.05）.The above levels were higher in intermittent group than healthy group [（5.08±1.24） mmol/L,（1.61±0.79） mmol/L,8.1%,（9.38±3.45） mg/L vs（3.86±0.77） mmol/L,（0.92±0.35） mmol/L,0.0%,（6.26±1.28） mg/L]（P〈0.05）.Conclusion：With the development of gout,levels of blood lipids and inflammatory factors increase.There is subclinical hypothyroidism in some patients.Attention should be paid to the thyroid function in patients with gout and active intervention for regulating lipid and inhibit inflammation should be adopted to protect the thyroid function and prevent further development of the disease.